Digirad Corporation Launches Molecular Breast Imaging Accessory for Expanded Use of ergo™ Imaging System

POWAY, CA -- (Marketwire) -- 02/21/13 -- Digirad Corporation (NASDAQ: DRAD), a leading provider of diagnostic imaging products, and personnel and equipment leasing services, today announced the launch of their Molecular Breast Imaging Accessory for the ergo™ Imaging System, further expanding the clinical flexibility of the ergo™ Imaging System for applications in the area of women's health, as well as in nuclear medicine where the ergo™ Imaging System is currently used for a wide variety of clinical applications.

The introduction of Digirad's Molecular Breast Imaging Accessory follows the U.S. FDA 510(k) market clearance recently received for expanded use of the ergo™ Imaging System, which includes Indications for Use to aid in the evaluation of lesions in the breast and other small body parts. When used for breast imaging, the ergo™ Imaging System can be used as an adjunct to mammography or other primary breast imaging modalities.

Digirad Chief Executive Officer Todd Clyde noted that this launch marks another key step in the company's strategy to expand its imaging technology footprint in the hospital through the use of flexible, portable systems with devices that have expanded diagnostics capabilities.

"We believe the Molecular Breast Imaging Accessory fills an important market need and is a natural addition to the ergo™ Imaging System," said Clyde. "Advanced diagnostic modalities are often necessary to help clinicians identify lesions in the breast, and our new Molecular Breast Imaging Accessory provides this capability. It is a cost-effective, non-dedicated option for molecular breast imaging that enhances the clinical capabilities and operational efficiencies of the ergo™ Imaging System."

source: DigiRad